Rocuronium BromideTGF-βR I kinase inhibitor CAS# 119302-91-9 |
- A-867744
Catalog No.:BCC1324
CAS No.:1000279-69-5
- Rivastigmine
Catalog No.:BCC1900
CAS No.:123441-03-2
- Rocuronium
Catalog No.:BCC1906
CAS No.:143558-00-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 119302-91-9 | SDF | Download SDF |
| PubChem ID | 441351 | Appearance | Powder |
| Formula | C32H53BrN2O4 | M.Wt | 609.68 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 155 mg/mL (254.23 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate;bromide | ||
| SMILES | CC(=O)OC1C(CC2C1(CCC3C2CCC4C3(CC(C(C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-] | ||
| Standard InChIKey | OYTJKRAYGYRUJK-FMCCZJBLSA-M | ||
| Standard InChI | InChI=1S/C32H53N2O4.BrH/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35;/h5,23-30,36H,1,6-21H2,2-4H3;1H/q+1;/p-1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Rocuronium Bromide is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal musclerelaxation during surgery or mechanical ventilation.
IC50 Value:
in vitro: Rocuronium reduced the indirectly elicited twitch tensions in normal (50% inhibitory concentration [IC(50)], 9.84 [9.64-10.04] μM, mean [95% confidence interval]) and all pretreated diaphragms (P < .01, n = 6) in a concentration-dependent fashion [1]. The ED95 of rocuronium is essentially the same for children as for adults. Its duration of action is similar to vecuronium, and it is shorter for children than for adults. Rocuronium is readily reversed with conventional doses of cholinesterase-inhibiting drugs [2]. Onset time until maximum block, duration until 25% recovery of twitch height, and recovery from 25 until 75% of twitch height were 1.7 (32), 53 (19) and 20 (37) min, respectively [3].
in vivo: Only 8.7 +/- 5.7% (SD) and 6.0 +/- 2.8% of an injected dose of ORG 9426 and ORG 9616 was excreted into the urine, respectively. Conversely, 54.4 +/- 9.2% and 52.4 +/- 9.2% of an injected dose of ORG 9426 and 35.7 +/- 12.2% and 46.8 +/- 9.7% of ORG 9616 were excreted into the bile in cats without and with renal pedicle ligation, respectively [4]. References: | |||||
Rocuronium Bromide Dilution Calculator
Rocuronium Bromide Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.6402 mL | 8.201 mL | 16.402 mL | 32.8041 mL | 41.0051 mL |
| 5 mM | 0.328 mL | 1.6402 mL | 3.2804 mL | 6.5608 mL | 8.201 mL |
| 10 mM | 0.164 mL | 0.8201 mL | 1.6402 mL | 3.2804 mL | 4.1005 mL |
| 50 mM | 0.0328 mL | 0.164 mL | 0.328 mL | 0.6561 mL | 0.8201 mL |
| 100 mM | 0.0164 mL | 0.082 mL | 0.164 mL | 0.328 mL | 0.4101 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Rocuronium Bromide is an aminosteroid non-depolarizing neuromuscular blocker.
- PE 154
Catalog No.:BCC7858
CAS No.:1192750-33-6
- Scutellarin methylester
Catalog No.:BCN2828
CAS No.:119262-68-9
- Avibactam
Catalog No.:BCC1384
CAS No.:1192500-31-4
- Gomisin S
Catalog No.:BCN3622
CAS No.:119239-49-5
- LX7101 HCL
Catalog No.:BCC6414
CAS No.:1192189-69-7
- PHT-427
Catalog No.:BCC2554
CAS No.:1191951-57-1
- 4-(1H-1,2,4-Triazol-1-ylmethyl)aniline
Catalog No.:BCC8645
CAS No.:119192-10-8
- CZC 54252 hydrochloride
Catalog No.:BCC6218
CAS No.:1191911-27-9
- CZC-25146
Catalog No.:BCC5371
CAS No.:1191911-26-8
- 10-Hydroxyscandine
Catalog No.:BCN6078
CAS No.:119188-47-5
- Coronarin B
Catalog No.:BCN6077
CAS No.:119188-38-4
- Coronarin D
Catalog No.:BCN6076
CAS No.:119188-37-3
- Atalantoflavone
Catalog No.:BCN4857
CAS No.:119309-02-3
- Pinobanksin 5-methyl ether
Catalog No.:BCN7775
CAS No.:119309-36-3
- 2-Benzyl-2-(dimethylamino)-4'-morpholinobutyrophenone
Catalog No.:BCC8563
CAS No.:119313-12-1
- Olean-12-ene-3,24-diol
Catalog No.:BCN6079
CAS No.:119318-15-9
- 2-Hydroxydiplopterol
Catalog No.:BCN7290
CAS No.:1193250-54-2
- CRANAD 2
Catalog No.:BCC6293
CAS No.:1193447-34-5
- 2-Deacetoxytaxinine J
Catalog No.:BCN7291
CAS No.:119347-14-7
- mAChR-IN-1
Catalog No.:BCC5512
CAS No.:119391-56-9
- 2,5-Dihydroxybenzaldehyde
Catalog No.:BCN6081
CAS No.:1194-98-5
- Salviolone
Catalog No.:BCN3141
CAS No.:119400-86-1
- Przewalskin
Catalog No.:BCN6080
CAS No.:119400-87-2
- LY2811376
Catalog No.:BCC2102
CAS No.:1194044-20-6
Pharmacodynamic comparison of rocuronium bromide between patients from the plateau area and from the plain area.[Pubmed:27339667]
J Evid Based Med. 2016 Aug;9(3):112-115.
OBJECTIVES: We aimed to conduct a pharmacodynamic comparison of Rocuronium Bromide between patients from the plateau area and from the plain area. METHODS: A total of 104 patients who received laparoscopic cholecystectomy in Sichuan Provincial People's Hospital and Aba Autonomous Prefecture People's Hospital from October 2015 to December 2015 were included in this study. Among them, 46 patients were from the plateau area and 58 were from the plain area. Both groups received total intravenous anesthesia (TIVA) with a dose of 0.6 mg/kg Rocuronium Bromide during induction. In the meantime, neuromuscular block was monitored using a train-of-four (TOF) stimulation mode. The onset time (time to achieve the lowest TOF value after the injection of Rocuronium Bromide), duration of maximal neuromuscular block (duration of lowest T1 value), time to 25% recovery, time to 75% recovery, recovery index (time from 25% recovery to 75% recovery), time to extubation, length of stay in Post Anesthesia Care Unit (PACU) and muscle strength upon PACU discharge were all recorded. RESULTS: The onset time, time to 25% recovery, time to 75% recovery and time to extubation were all significantly prolonged in patients from the plateau area after receiving one single dose of Rocuronium Bromide (P < 0.05). However, both groups didn't show any significant difference in maximal neuromuscular block, recovery index (time from 25% recovery to 75% recovery), length of stay in PACU, or muscle strength upon PACU discharge (P > 0.05). CONCLUSIONS: Compared to patients from the plain area, patients from the plateau area showed prolonged onset time of Rocuronium Bromide, reduced metabolic capabilities, and longer duration of muscular relaxation.
Rocuronium Bromide Inhibits Inflammation and Pain by Suppressing Nitric Oxide Production and Enhancing Prostaglandin E2 Synthesis in Endothelial Cells.[Pubmed:28043117]
Int Neurourol J. 2016 Dec;20(4):296-303.
PURPOSE: Rocuronium Bromide is a nondepolarizing neuromuscular blocking drug and has been used as an adjunct for relaxation or paralysis of the skeletal muscles, facilitation of endotracheal intubation, and improving surgical conditions during general anesthesia. However, intravenous injection of Rocuronium Bromide induces injection pain or withdrawal movement. The exact mechanism of Rocuronium Bromide-induced injection pain or withdrawal movement is not yet understood. We investigated whether Rocuronium Bromide treatment is involved in the induction of inflammation and pain in vascular endothelial cells. METHODS: For this study, calf pulmonary artery endothelial (CPAE) cells were used, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, Western blot, nitric oxide detection, and prostaglandin E2 immunoassay were conducted. RESULTS: Rocuronium Bromide treatment inhibited endothelial nitric oxide synthase and suppressed nitric oxide production in CPAE cells. Rocuronium Bromide activated cyclooxygenase-2, inducible nitric oxide synthase and increased prostaglandin E2 synthesis in CPAE cells. CONCLUSIONS: Rocuronium Bromide induced inflammation and pain in CPAE cells. Suppressing nitric oxide production and enhancing prostaglandin E2 synthesis might be associated with Rocuronium Bromide-induced injection pain or withdrawal movement.
Ease of intubation: A randomized, double-blind study to compare two doses of rocuronium bromide for endotracheal intubation.[Pubmed:27746543]
Anesth Essays Res. 2016 Sep-Dec;10(3):512-515.
CONTEXT: Clinical need for a nondepolarizing agent with a rapid onset time and a brief duration of action has led to the development of Rocuronium Bromide. AIMS: The aim of this study was to evaluate optimal dose of Rocuronium Bromide for intubation and to compare the onset time, duration of action, intubating conditions, and hemodynamic effects of two doses of Rocuronium Bromide. SETTINGS AND DESIGN: A prospective, randomized, double-blind study. MATERIALS AND METHODS: All the patients were divided in a randomized, double-blind fashion into two groups of twenty patients each. Group I patients received Rocuronium Bromide 0.6 mg/kg intravenously and intubated at 60 s, Group II patients received Rocuronium Bromide 0.9 mg/kg and intubated at 60 s. The neuromuscular block was assessed using single twitch stimulation of 0.1 Hz at adductor pollicis muscle of hand at every 10 s. STATISTICAL ANALYSIS USED: The results were compiled and analyzed statistically using Chi-square test for qualitative data and Student's t-test for quantitative data. RESULTS: Time of onset was significantly shorter (P < 0.01) and duration of action was prolonged (P < 0.001) for Group II as compared to Group I. The intubating conditions were (excellent + good) in 100% patients of Group II and (excellent + good) in 80% of Group I. There was no significant change in pulse rate and mean arterial pressure from the baseline value after the administration of muscle relaxants in either of the two groups. CONCLUSIONS: Rocuronium Bromide 0.9 mg/kg is a safer alternative to Rocuronium Bromide 0.6 mg/kg for endotracheal intubation with shorter time of onset and better intubating conditions.
